title: Primary malignant B-cell-type dural lymphoma: Case report.
abstract: BACKGROUND
  The primary malignant dural lymphoma of B-cell type is rare. Our review of the literature (24 cases) indicated that patients with this tumor had female predominance, immunocompetency, and longer survival compared with those with primary malignant intracerebral lymphomas. Based on its clinicopathological features, this dural lymphoma may be classified differently from other types of malignant lymphomas in the central nervous system.
  
  
  METHODS
  The authors report an example of a patient who had a favorable course of malignant dural lymphoma. A 59-year-old woman presented with primary malignant dural lymphoma in the frontal area. Histological diagnosis was a diffuse large B-cell-type lymphoma of intermediate malignancy, but MIB-1 index was extremely high. Subtotal tumor removal was followed by 4 courses of chemotherapy. Thirty months after surgery, the patient is asymptomatic with no MRI evidence of recurrence. A combination of subtotal resection and chemotherapy for a primary malignant dural lymphoma is an effective means to attempt cure of this tumor.
  
  
  CONCLUSIONS
  These rare tumors may be managed successfully by subtotal resection and postoperative treatment. We believe that chemotherapy is the treatment of choice after subtotal resection of malignant dural lymphomas, as experienced in our case.
authors.affiliation: Department of Neurosurgery, Kochi University School of Medicine, Nankoku-City, Kochi-Prefecture 783-8505 Japan. yamadasm@med.kochi-u.ac.jp
authors.forename: Shoko M
authors.initials: SM
authors.lastname: Yamada
authors.forename: Naoki
authors.initials: N
authors.lastname: Ikawa
authors.forename: Shinichi
authors.initials: S
authors.lastname: Toyonaga
authors.forename: Hiromichi
authors.initials: H
authors.lastname: Nakabayashi
authors.forename: Kae
authors.initials: K
authors.lastname: Chang Park
authors.forename: Keiji
authors.initials: K
authors.lastname: Shimizu
mesh_terms: D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D002550:Cerebral Veins / Q000000981:diagnostic imaging / Q000473:pathology; D003399:Craniotomy; D019299:Decompression, Surgical; D004388:Dura Mater / Q000000981:diagnostic imaging / Q000473:pathology* / Q000601:surgery; D004824:Epidural Space / Q000000981:diagnostic imaging / Q000473:pathology / Q000601:surgery; D005260:Female; D005625:Frontal Lobe / Q000473:pathology; D006801:Humans; D008214:Lymphocytes / Q000473:pathology; D016393:Lymphoma, B-Cell / Q000175:diagnosis* / Q000188:drug therapy / Q000601:surgery; D008279:Magnetic Resonance Imaging; D008577:Meningeal Neoplasms / Q000175:diagnosis* / Q000188:drug therapy / Q000601:surgery; D008875:Middle Aged; D011859:Radiography; D011877:Radionuclide Imaging; D013794:Thallium Radioisotopes; D016896:Treatment Outcome
chemical_list: D013794:Thallium Radioisotopes